Conference abstract · 2019
Conference abstract
Addressing biosimilars: A future perspective
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
B iopharmaceuticals represent a fast-growing and important class of drugs for the treatment of various severe diseases like growth disorders, acute myocardial infraction, leukemia, neutropenia, ischemic events etc. ?Biosimilars? (in Europe) or ?follow-on biologic? (in US) are basically protein molecules which are similar, but not identical to, an existing available approved product. In contrast to available generic drug, it is next to impossible to create copycat of a biological drug because of intricate nature of biological (protein) molecules. Research also suggests that because of inactivation by the body?s normal immune response, protein molecules lose their efficacy when used for longer duration or may provide a more rapid immune response than original drug; thereby results serious side effects in patients. In ad dition, biosimilars have enormous regulatory issues as they are not considered to be generic drugs. In contrast to generic drugs, there is no adequate guidance available for the approval of biosimilars in regulated market which in turn provide additional advantage to innovator to survive in the market for longer period. Compare to US regulations where there are lack of legislation for formal approval process, Europe has more conspicuous guidance on biosimilars. Based upon above scenario there is huge expectation of industries from regulatory bodies to provide formal guidance which reduce healthcare expenditure, increase access of biological drugs to patients by considering their safety and encourage development of affordable and quality biosimilars. By keeping above mentioned scenario in mind, authors have made an attempt to discuss following issues related to biosimilars: safety, need for clinical trials and indication specific approval, product identifiability and traceability, post-marketing risk management plans required, automatic substitution, nam ing and labeling/ prescription rules and how biosimilars should be evaluated by regulators, pharmacist, physicians and patients. PDF HTML
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract
Glucagon biosimilar: New perspective for low-price biopharmaceutical products for SUS
Conference abstract
A global perspective on the challenges of GLP/GCLP-Bioanalysis for biosimilars
Conference abstract
Strategies and innovation in biosimilar drug development, achievement and challenges ? An Indian perspective
Commentary · 30 Sep 2024
Exploring the Impact of Biosimilars on Biopharmaceutical Markets: Trends and Future Directions
More from this journal
The newest in Journal of Bioequivalence & Bioavailability.
Article · 5 Oct 2026
Long COVID in pediatric and young adult patients: a review of evaluation for microvascular changes, endothelial dysfunction, and arterial stiffness
Article · 12 Jun 2026
Advances in Bioavailability Through Innovative Drug Delivery Systems and Formulation Technologies
Article · 12 Jun 2026
Bioequivalence Study Design and Methodological Approaches in Generic Drug Evaluation
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Bioequivalence & Bioavailability
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Sumit Kumar Jain”
- BylineArticles whose byline prints “N.Siva Prasad”
- BylineArticles whose byline prints “Pallab de”
